Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 92,849

Document Document Title
WO/2019/008029A1
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...  
WO/2019/007356A1
There is provided topical pharmaceutical formulations comprising montelukast,or a pharmaceutical acceptable salt of solvate thereof,as well as combination products comprising(a)at least one mussel adhesive protein or a derivative...  
WO/2019/007696A1
The present invention discloses compounds according to Formula (I) Wherein R1, R2, L, A1, A2, A3, Cy and the subscript n are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) recep...  
WO/2019/007382A1
Disclosed are an indole-formamide derivative, a preparation method therefor and the use thereof in medicine. In particular, disclosed are an indole-formamide derivative as shown in general formula (I), a preparation method therefor, a ph...  
WO/2019/009434A1
The present invention relates to: a compound that is formed by linking the α carbonyl group of aspartic acid directly or via a linker to at least 50% of all of the terminal groups of a dendritic polymer that has a plurality of terminal ...  
WO/2019/006691A1
The present application provides a pharmaceutical composition for treating cerebral hemorrhage. The pharmaceutical composition comprises a peptide containing an amino acid sequence of YEKLLDTEI (SEQ ID NO: 1) or a functional variant ther...  
WO/2019/007284A1
Disclosed are a new carbazolamide derivative as shown in general formula I and having the effect of regulating RORγt activity or a salt thereof and a preparation method therefor. Also disclosed is the use of the carbazolamide derivative...  
WO/2019/008011A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...  
WO/2019/006690A1
Provided are a polypeptide pharmaceutically acceptable salt and a pharmaceutical composition thereof, said polypeptide containing an amino acid sequence YEKLLDTEI or functional variants thereof.  
WO/2019/003159A1
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a...  
WO/2019/003162A1
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.  
WO/2019/001459A1
Disclosed in the present invention are a peptide compound, an application thereof, and a composition containing the same. Provided in the present invention are a peptide compound represented by formula I, a pharmaceutically acceptable sa...  
WO/2019/000105A1
Provided herein are stabilized chimeric Fabs derived from a parent chimeric Fab having a lambda light chain. The stabilized chimeric Fabs comprise an immunoglobulin heavy chain polypeptide construct from the parent chimeric Fab, having a...  
WO/2019/005685A1
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...  
WO/2019/006126A1
Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and composition...  
WO/2019/001342A1
The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present ...  
WO/2019/001416A1
The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in...  
WO/2019/001572A1
The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated...  
WO/2019/004466A1
Provided is a medicine for safely treating a patient who needs to be treated with the use of pemafibrate, a salt thereof or a solvate of the same (hereinafter called "pemafibrate treatment"). The medicine for treating a patient who needs...  
WO/2019/000045A1
The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases i...  
WO/2019/002607A1
The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.  
WO/2019/004444A1
Provided is an osteogenesis promoter for promoting the differentiation of osteoblast precursor cells into osteoblast cells, and the calcification of the osteoblast cells. The osteogenesis promoter includes, as an active ingredient, a sub...  
WO/2018/233728A1
Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain ...  
WO/2018/237084A1
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras su...  
WO/2018/234354A1
The invention relates to novel 3-indole and 3-indazole compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents. variables and indices are as defined in the description, and to th...  
WO/2018/234342A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/233655A1
The present invention provides a novel compound having selective inhibitory activity against Btk and better metabolic stability.  
WO/2018/234343A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/234861A1
The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level...  
WO/2018/234345A1
Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/235851A1
The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which ...  
WO/2018/235813A1
A compound represented by the formula, which has an RORγt inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.  
WO/2018/236814A2
The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and...  
WO/2018/232452A1
A method of treating or preventing inflammation in the lung by administering a high concentration of an inhaled chelating agent, in particular CaEDTA.  
WO/2018/233437A1
The present invention provides a new crystal form of baricitinib, a preparation method thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a JAK kinase inhibitor or a pharmaceutic...  
WO/2018/233571A1
The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugat...  
WO/2018/232735A1
Provided is use of regulator in preparation of a medicament for regulating at least one of the following, wherein the regulator is used for activating or inhibiting Piezo: blood vessel development; blood pressure regulation; red blood ce...  
WO/2018/233553A1
Disclosed are a fused bicyclic compound and the use thereof in a medicine, particularly a novel fused bicyclic compound used as an ASK1 activity regulator and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a...  
WO/2018/234353A1
The invention relates to novel indole and indazole compounds characterized in that the compound has general formula (I), in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their...  
WO/2018/230695A1
The problem addressed by the present invention is to provide an agent for the prevention or treatment of fat-related diseases and/or inflammation. The present invention provides an agent for the prevention or treatment of fat-related dis...  
WO/2018/229193A1
The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tauto...  
WO/2018/230687A1
Provided is a drug for external use which comprises lidocaine lactate and diclofenac or a salt thereof, wherein lidocaine and diclofenac used as active ingredients show excellent transdermal absorption properties and ensure a skin permea...  
WO/2018/230733A1
[Problem] The main purpose of the present invention is to provide an external preparation for the skin, characterized by being able to enhance insensible perspiration that is a type of perspiration which can moisturize the skin. [Solutio...  
WO/2018/228934A1
The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical pre...  
WO/2018/232260A1
The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with ...  
WO/2018/228430A1
Disclosed is the use of isoferulic acid, an isoferulic acid-containing traditional Chinese medicine extract and Cimicifugae foetidae in the preparation of a drug or functional healthcare product for autoimmune diseases. Also disclosed ar...  
WO/2018/231614A1
Methods for treating systemic lupus erythematosus (SLE) are disclosed, based on administering to a subject with SLE an amount effective to treat the subject of a polypeptide including antiogensin 1-7 (A(l-7)), N le3A 1 -7, or a compound ...  
WO/2018/229197A1
The present invention relates to bicyclic heteroaromatic urea or carbamate compounds of formula I where the variables are as defined in the claims and the description. The invention moreover relates to a pharmaceutical composition contai...  
WO/2018/228474A1
Disclosed are a compound as shown in general formula I, a pharmaceutically acceptable salt, an isomer or a mixture thereof, and a solvate, a polymorph, a stable isotope derivative or a prodrug thereof. The compound of the present inventi...  
WO/2018/230713A1
The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF-β signaling in corneal endothelial cells. Provided by the present invention is a com...  

Matches 1 - 50 out of 92,849